Article

Nerve growth factor level may be marker for neurogenic overactive bladder, interstitial cystitis

Author(s):

Penny Allen

Nerve growth factor (NGF) levels in urine could prove a useful biomarker for interstitial cystitis/painful bladder syndrome (IC/PBS) and neurogenic overactive bladder.

Related Videos
Ekene Enemchukwu, MD, on vaginal estrogen for genitourinary syndrome of menopause
Ekene Enemchukwu, MD, on vaginal estrogen for genitourinary syndrome of menopause
Human kidney cross section on science background. 3d render. | Image Credit: © Rasi - stock.adobe.com
Expert discusses innovations in single-use ureteroscopes for stones
1 expert in this video
Resective Surgery and Minimally Invasive Procedures For BPH
Naeem Bhojani, MD, discusses WATER III data on Aquablation vs enucleation for BPH
Naeem Bhojani, MD, discusses WATER III data on Aquablation vs enucleation for BPH
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Timothy Lyon, MD, on recent change to outpatient complications metric in urology rankings
Timothy Lyon, MD, on recent change to outpatient complications metric in urology rankings
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Checkpoint Inhibitors for Treatment of NMIBC
Checkpoint Inhibitors for Treatment of NMIBC
Communication of Treatment Options for High-Risk NMIBC
Communication of Treatment Options for High-Risk NMIBC
Related Content
What urologists can expect in Q2 of 2025
April 7th 2025

What urologists can expect in Q2 of 2025

Hannah Clarke Benjamin P. Saylor
A lookahead of the notable FDA decisions and conferences slated for Q2 2025.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
blur image background of corridor in hospital or clinic image | Image Credit: @ whyframeshot - stock.adobe.com
April 4th 2025

UroLift may offer improved early recovery period vs Rezūm for BPH

Hannah Clarke
“The differences in patient experience between UroLift System and Rezūm, particularly in terms of early recovery, sexual function, and overall satisfaction, are key considerations for both clinicians and patients selecting a treatment path," says Mark Rochester, MD, FRCS.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC
April 3rd 2025

Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC

Mehmet Asim Bilen, MD Hannah Clarke
"The combination demonstrated clinical activity and an acceptable safety profile in the perioperative setting for locally advanced, non-metastatic clear cell RCC," says Mehmet Asim Bilen, MD.
Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: @ Dr_Microbe - stock.adobe.com
April 3rd 2025

CD46-targeting ADC shows encouraging clinical activity in mCPRC

Hannah Clarke
The company plans to initiate the phase 2 monotherapy trial by mid-year.
© 2025 MJH Life Sciences

All rights reserved.